Rx-360 International Pharmaceutical Supply Chain Consortium is a 501(c)(6) organization based in Philadelphia, Pennsylvania, registered in 2012, with $4,971,657 in FY2024 revenue. CharityIndex grades it B.
Revenue (FY2024)
$5.0M
▲ 18.0% vs prior year
Employment median: $367K
Expenses (FY2024)
$4.2M
Net assets
$3.2M
Employees
—
Rated on 2 of 4 criteria — the rest aren't reported in this filing type.
Held down by its weakest criterion — a strong score on one criterion can't hide a weak one.
How the rating works →Measures how much of every dollar spent actually reaches programs, plus what it costs to raise $100 of donations. The worse of the two measures sets the letter (85%+ to programs is an A; under $15 to raise $100 is an A), averaged over the three most recent filings. Not scored for Rx-360 International Pharmaceutical Supply Chain Consortium— this filing type doesn't report it, and the rating simply skips it (never counts it against the organization). See the exact thresholds →
Measures whether the organization is built to last: how many months its reserves would cover expenses (3+ months earns an A-range score, but hoarding 5+ years of budget is capped) and whether it runs a surplus or a deficit. For Rx-360 International Pharmaceutical Supply Chain Consortium: 9 mo reserves · +16% margin earns a A on this criterion. See the exact thresholds →
Checks how the organization is run, from its own Form 990: an independent board majority, a board of five or more, conflict-of-interest, whistleblower and document-retention policies, and independently audited financials. The share of disclosed checks that pass sets the letter. Not scored for Rx-360 International Pharmaceutical Supply Chain Consortium— this filing type doesn't report it, and the rating simply skips it (never counts it against the organization). See the exact thresholds →
Counts five disclosure signals: a recent filing, a mission statement, program descriptions, a listed website, and the full expense breakdown. More disclosure, better letter. For Rx-360 International Pharmaceutical Supply Chain Consortium: 2 of 5 disclosure signals earns a C on this criterion. See the exact thresholds →
Show this grade on your website
A live seal — it updates automatically when the grade changes and links donors to this verified profile.
Revenue grew from $1.6M (FY2013) to $5.0M (FY2024) across 11 reported years.
Financial snapshot
Operating margin
15.7%
Revenue exceeded expenses in the latest fiscal year.
Total assets
$5.8M
Total liabilities
$2.6M
Net assets
$3.2M
| Fiscal year | Revenue | Expenses | Net assets | Total assets | Form |
|---|---|---|---|---|---|
| 2024 | $4,971,657▲18.0% | $4,190,451▲18.3% | $3,197,859▲27.2% | $5,825,545▲59.1% | 990 |
| 2023 | $4,214,492▲17.4% | $3,541,635▲18.5% | $2,514,318▲36.5% | $3,660,812▲22.0% | 990 |
| 2022 | $3,588,442▲21.9% | $2,988,163▲45.5% | $1,841,461▲48.4% | $3,000,257▲40.4% | 990 |
| 2021 | $2,943,923▲63.2% | $2,053,844▲32.1% | $1,241,182▲254% | $2,136,683▲122% | 990 |
| 2020 | $1,803,758▲22.9% | $1,555,010▲4.4% | $351,103▲275% | $961,291▲35.6% | 990 |
| 2019 | $1,467,673▼23.8% | $1,489,161▼19.2% | $93,571▼18.7% | $708,888▼13.1% | 990 |
| 2018 | $1,927,037▲17.2% | $1,843,250▲21.0% | $115,059▼39.0% | $815,374▼40.6% | 990 |
| 2017 | $1,643,664▼7.5% | $1,523,943▼0.1% | $188,575▼42.8% | $1,372,044▲135% | 990 |
| 2015 | $1,776,779▲3.8% | $1,524,867▼3.9% | $329,869▲34.5% | $584,546▼15.2% | 990 |
| 2014 | $1,712,455▲8.6% | $1,585,951▲8.7% | $245,248▲107% | $689,126▲63.2% | 990 |
| 2013 | $1,577,224 | $1,458,480▼16.9% | $118,744 | $422,161▼12.6% | 990 |
| 2012 | — | $1,755,594▲33.3% | $0 | $483,272▲17.3% | 990 |
| 2011 | — | $1,316,749 | $0 | $411,952 | 990 |
Original Form 990 PDFs (the Form column) are served by ProPublica Nonprofit Explorer, as filed with the IRS. Create a free account to download the CSV report.
Explore more
Data for Rx-360 International Pharmaceutical Supply Chain Consortium (EIN 45-2410498) comes from the IRS Business Master File and e-filed Form 990 returns, via CharityIndex. Figures reflect what the organization reported to the IRS for each fiscal year.